Læknablaðið - 15.09.2000, Side 21

FRÆÐIGREINAR / LÍFFÆRAFLUTNINGAR
36. Helderman J. Review and preview of anti-T cell antibodies.
Transplant Proc 1995; 7: 8-9.
37. Suthanthiran M, Morris R, Strom T. Immunosuppressants:
Cellular and molecular mechanisms of action. Am J Kidney
Dis 1996; 28:159-72.
38. Abramowicz D, Aschandene L, Goldman M, Crusiaux A,
Vereerstraten P, De Pauw L, et al. Release of tumor necrosis
factor, interleukin-2, and gamma-interferon in serum after
injection of OKT3 monoclonal antibody in kidney transplant
recipients. Transplantation 1989; 47: 606-8.
39. Bemelman F, Buysman S, Surachno J, Wilmink J, Schellekens
P, ten Berge I. Pretreatment with divided doses of steroids
strongly decreases side effects of OKT3. Kidney Int 1994; 46:
1674-9.
40. Nashan B, Moore R, Amlot P, Schmidt A-G, Abeywickrama
K, Soulillou J-P. Randomised trial of basiliximab versus
placebo for control of acute cellular rejection in renal allograft
recipients. Lancet 1997; 350:1193-8.
41. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M,
Halloran P, et al. Interleukin-2 receptor blockade with
daclizumab to prevent acute rejection in renal transplantation.
Daclizumab Triple Therapy Study Group. N Engl J Med 1998;
338:161-5.
42. Norman DJ, Kahana L, Stuart FPJ. A randomized clinical trial
of induction therapy with OKT3 in kidney transplantation.
Transplantation 1993; 55:44-50.
43. Szczech L, Berlin J, Aradhye S, Grossman R, Feldman H.
Effect of anti-Iymphocyte induction therapy on renal allograft
survival: a meta-analysis. J Am Soc Nephrol 1997; 8:1771-7.
44. Novick A, Hwei H, Steinmuller D, Streem SB, Cunningham
RJ, Steinhilber D, et al. Detrimental effect of cyclosporine on
initial function of cadaver renal allografts following extended
preservation: results of randomized prospective trial.
Transplantation 1986; 42:154-8.
45. Cecka JM, Yong WC, Terasaki PI. Analyses of the UNOS
Scientific Renal Transplant Registry at three years - early
events affecting transplant success. Transplantation 1992; 53:
59-64.
46. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal
transplantation. Transplantation 1995; 60:1220-4.
47. Hricik D, O'TooIe M, Schulak J, Herson J. Steroid-free
immunosuppression in cyclosporine-treated renal transplant
recipients: a meta-analysis. J Am Soc Nephrol 1993; 4:1300-5.
48. Ortho Multicenter Transplant Study Group. A randomized
clinical trial of OKT3 monoclonal antibody for acute rejection
of cadaveric renal transplants. N Engl J Med 1985; 313:337-42.
49. Adams D, Neuberger J. Treatment of acute rejection. Semin
Liver Dis 1992; 12: 80-8.
50. Solomon H, Gonwa T, Mor E, Holman MJ, Gibbs J,
Watemberg I, et al. OKT3 rescue for steroid-resistant
rejection in adult liver transplantation. Transplantation 1993;
55: 87-91.
51. Jordan M, Shapiro R, Vivas S, Scantlebury V, Rhandhawa P,
Carrieri G, et al. FK506 „rescue“ for resistant rejection of
renal allografts under primary cyclosporine
immunosuppression. Transplantation 1994; 57: 860-5.
52. Woodle E, Thistlethwaite J, Gordon J, Laskow D, Deierhoi
MH, Burdick J, et al. A multicenter trial of FK506
(tacrolimus) therapy in refractory acute renal allograft
rejection. Transplantation 1996; 62: 594-9.
53. Armitage J, Kormos R, Morita S, Fung J, Marrone G, Hardesty
R, et al. The clinical trial of FK-506 as primary and rescue
immunosuppression in adult cardiac transplantation. Ann
Thor Surg 1992; 54: 205-10.
54. The Mycophenolate Mofetil Renal Transplantation Study
Group. Mycophenolate mofetil for the treatment of a first
acute renal allograft rejection. Transplantation 1998; 65: 235-
41.
55. Fishman J, Rubin R. Infection in organ-transplant recipients.
N Engl J Med 1998; 338:1741-51.
56. Rubin R, Wolfson J, Cosimi A, Tolkoff-Rubin N. Infection in
the renal transplant patient. Am J Med 1981; 70:405-11.
57. Rubin R. Impact of cytomegalovirus infection on organ
transplant recipients. Rev Infect Dis 1990; 12/Suppl. 7: S754-
S766.
58. Patton D, Wilkowski C, Hanson C, Shapiro R. Epstein-Barr
virus determines clonality in post-transplant
lymphoproliferative disorders. Transplantation 1990; 49:1080-
4.
59. Tolkoff-Rubin N, Cosimi A, Russel P, Rubin R. A controlled
study of trimethoprim-sulfamethoxazole prophylaxis of
urinary tract infections in renal transplant recipients. Rev
Infect Dis 1982; 4: 614-8.
60. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C.
Cytomegalovirus prophylaxis with antiviral agents in solid
organ transplantation: a meta-analysis. Transplantation 1998;
65: 641-7.
61. Hibberd P, Tolkhoff-Rubin N, Conti D, Stuart F, Thistlethwaite
J, Neylan J, et al. Preemptive ganciclovir therapy to prevent
cytomegalovirus disease in cytomegalovirus antibody-positive
renal transplant recipients. Ann Int Med 1995; 123:18-26.
62. First M, Peddi V. Malignancies complicating organ
transplantation. Transplant Proc 1998; 30: 2768-70.
63. Penn I. Malignancy. Surg Clin North America 1994; 74: 1247-
57.
64. Penn I. The changing patterns of posttransplant malignancies.
Transplant Proc 1991; 23:1101-3.
65. Penn I. Cancers complicating organ transplantation. N Engl J
Med 1990; 232:1767-8.
66. Swinnen L, Constanzo-Nordin M, Fisher S, O'Sullivan E,
Johnson MR, Heroux AL, et al. Increased incidence of
lymphoproliferative disorder after immunosuppression with
the monoclonal antibody OKT3 in cardiac transplant
recipients. N Engl J Med 1990; 323:1723-8.
67. Nalesnik M, Jaffe R, Starzl T, Demetris AJ, Porter K, Burnham
JA, et al. The pathology of posttransplant lymphoproliferative
disorders occurring in the setting of cyclosporine A-
prednisone immunosuppression. Am J Pathol 1988; 133: 173-
92.
68. Quinbi W, Al-furayh O, Almeshari K, Lin SF, Sun R, Heston L,
et al. Serologic association of human herpesvirus eight with
posttransplant Kaposi's sarcoma in Saudi Arabia.
Transplantation 1998; 65: 583-5.
69. First M, Neylan J, Rocher L, Tejani A. Hypertension after
renal transplantation. J Am Soc Nephrol 1994; 4/Suppl. 1: S30-
S36.
70. Textor S, Canzanello V, Taler S, Schwartz L, Augustine J.
Hypertension after liver transplantation. Liver Transpl Surg
1995; 1: 20-8.
71. Kobashigawa J, Kasiske B. Hyperlipidemia in solid organ
transplantation. Transplantation 1997; 63: 331-8.
72. Hohage H, Arlt M, Bruckner D, Dietl K, Zidek W, Spieker C.
Effects of cyclosporine A and FK 506 on lipid metabolism and
fibrinogen in kidney transplant recipients. Clin Transplant
1997;11:225-30.
73. Satterthwaite R, Aswad S, Sunga V, Shidban H, Bogaard T,
Asai P, et al. Incidence of new-onset hypercholesterolemia in
renal transplant patients treated with FK506 or cyclosporine.
Transplantation 1998; 65:446-9.
74. Arnadottir M, Berg A. Treatment of hyperlipidemia in renal
transplant recipients. Transplantation 1997; 63:339-45.
75. Pattison J, Petersen J, Kuo P, Valantine V, Robbins C,
Theodore J. The incidence of renal failure in one hundred
consecutive heart-Iung transplant recipients. Am J Kidney Dis
1995; 26: 643-8.
76. Fisher N, Nightingale P, Gunson B, Lipkin G, Neuberger J.
Chronic renal failure following liver transplantation.
Transplantation 1998; 66: 59-66.
77. Myers B, Newton L. Cyclosporine-induced chronic
nephropathy: An obliterative microvascular injury. J Am Soc
Nephrol 1991; 2/Suppl. 1: S45-S52.
78. Gonwa T, Mai M, Pilcher J, Johnson C, Pierson S, Capehart J,
et al. Stability of long-term renal function in heart transplant
patients treated with induction therapy and Iow-dose
cyclosporine. J Heart Lung Transplant 1992; 11: 926-8.
79. Cvetkovic M, Mann G, Romero D, Liang X, Ma Y, Jee WS, et
al. The deleterious effects of Iong-term cyclosporine A,
cyclosporine G, and FK506 on bone mineral metabolism in
vivo. Transplantation 1994; 57:1231-7.
Læknablaðið 2000/86 565